News and Announcements
MedAdvisor Signs Strategic Agreement with Arrow Pharmaceuticals
- Published June 01, 2016 2:46PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st June 2016, ASX Announcement
Highlights:
- MedAdvisor has sign a strategic agreement with Arrow Pharmaceuticals, one of Australia’s largest generic pharmaceutical manufacturers
- Arrows Pharmaceuticals’ 35 plus strong national sales teams to promote the MedAdvisor platform to its extensive first-line customer base of over 1,100 pharmacies from June 2016
- Strong platform validation with MedAdvisor now partnered with Australia’s two largest generic companies: Apotex and Arrow Pharmaceuticals
- Aligns with MedAdvisor’s strategy to substantially increase its referrer and patient customer base to drive revenue and growth
MedAdvisor Limied (ASX:MDR, the Company), Australia’s leading digital medication adherence company, is pleased to announce that it has signed a binding strategic agreement with Arrow Pharmaceuticals, Australia’s second largetst generic pharmaceutical manufactures, following the announcement of its Memorandum of Understanding in March 2016.
To view the full announcement, please click on the button below.